Daily Cosmetic Research Analysis
Three studies stand out in cosmetic and aesthetic medicine: a preclinical biomaterials paper engineering a collagen XVII-loaded dissolving microneedle patch for androgenic alopecia, a network meta-analysis clarifying postoperative pain differences among thyroidectomy approaches with cosmetic implications, and an ex vivo evaluation comparing at-home tooth bleaching agents for efficacy and enamel safety. Together, they emphasize targeted regeneration, patient-centered surgical selection, and produ
Summary
Three studies stand out in cosmetic and aesthetic medicine: a preclinical biomaterials paper engineering a collagen XVII-loaded dissolving microneedle patch for androgenic alopecia, a network meta-analysis clarifying postoperative pain differences among thyroidectomy approaches with cosmetic implications, and an ex vivo evaluation comparing at-home tooth bleaching agents for efficacy and enamel safety. Together, they emphasize targeted regeneration, patient-centered surgical selection, and product safety-performance balance.
Research Themes
- Regenerative biomaterials and transdermal delivery for aesthetic dermatology
- Patient-centered selection of thyroidectomy approaches balancing cosmetics and recovery
- Safety-efficacy profiling of at-home cosmetic dental bleaching
Selected Articles
1. Engineered collagen XVII-loaded dissolving microneedle patch for promoting hair regrowth in androgenic alopecia.
This preclinical study implicates collagen XVII downregulation in an androgenic alopecia-like mouse model and engineers a dissolving microneedle patch to deliver a recombinant COL17 fragment. The platform targets follicular morphology, proliferation, and angiogenesis deficits that accompany AGA, aiming to improve transdermal delivery and adherence compared with current therapies.
Impact: It introduces a mechanistically targeted, patient-friendly transdermal therapy concept for AGA, a high-prevalence aesthetic condition with limited options. The microneedle strategy could generalize to other hair disorders.
Clinical Implications: If validated in humans, a COL17-loaded dissolving microneedle could complement or offer an alternative to minoxidil/finasteride, improving adherence and localized delivery while reducing systemic exposure.
Key Findings
- Collagen XVII is significantly downregulated in a testosterone-induced AGA-like mouse model.
- Downregulation correlates with abnormal hair follicle morphology, reduced proliferation, and impaired angiogenesis.
- A recombinant human COL17 fragment (800–1300 aa) was engineered and paired with a dissolving microneedle delivery approach to promote hair regrowth.
Methodological Strengths
- Pathophysiology-informed target (COL17) identified in an in vivo AGA-like model
- Engineering of a patient-friendly dissolving microneedle delivery system
Limitations
- Preclinical model; no human efficacy or safety data reported
- Quantitative outcomes and long-term safety are not detailed in the abstract
Future Directions: Conduct dose-ranging and safety studies in large animals, followed by early-phase human trials assessing scalp delivery kinetics, hair regrowth endpoints, and safety versus standard therapies.
Androgenic alopecia (AGA), the most common form of progressive hair loss in both males and females, significantly impacts patients' quality of life and confidence. Current therapies, such as minoxidil, are limited by poor patient compliance and low transdermal bioavailability, highlighting the need for more effective treatments. In this study, we identified collagen XVII (COL17) as a key player in AGA-like model pathogenesis, observing its significant downregulation in a testosterone-induced AGA-like mouse model. This reduction was accompanied by abnormal hair follicle morphology, decreased proliferation and impaired angiogenesis. To address this, we developed recombinant human COL17 fragment (800-1300 aa) (rhCOL17p) expressed and purified from
2. Postoperative pain outcomes following thyroidectomy: a systematic review and network meta-analysis of various surgical approaches.
Across 61 studies (n=9,780), MIVAT and the transoral approach consistently yielded lower postoperative pain than conventional open and several remote-access techniques, particularly on day 1 and sustained to one month. Robotic platforms did not universally outperform endoscopic ones, though robotic retroauricular and transoral approaches showed lower pain in some comparisons.
Impact: Clarifies pain outcomes among cosmetically favorable thyroidectomy techniques, informing patient-centered decisions where scar location and recovery are critical.
Clinical Implications: When prioritizing reduced pain and improved cosmesis, MIVAT or transoral approaches can be considered, balancing surgeon expertise, resource availability, and oncologic/safety considerations.
Key Findings
- Network meta-analysis of 61 studies (n=9,780) compared MIVAT and five remote-access approaches versus conventional open surgery.
- MIVAT and transoral approach had the lowest postoperative pain at day 1 and maintained benefits at 1 week and 1 month.
- Retroauricular and bilateral axillo-breast approaches had higher early pain; robotic vs endoscopic differences were not significant overall.
Methodological Strengths
- PRISMA-guided systematic review with frequentist random-effects network meta-analysis
- Large evidence base spanning 9,780 patients and multiple approaches
Limitations
- Likely heterogeneity and inclusion of nonrandomized studies may introduce bias
- Pain measures and follow-up time points varied across studies
Future Directions: Prospective, standardized patient-reported outcomes across approaches and stratified analyses (e.g., benign vs malignant, extent of surgery) will refine guidance.
PURPOSE: Remote-access thyroidectomy techniques and minimally invasive video-assisted thyroidectomy (MIVAT) have been developed to optimize cosmetic outcomes and potentially improve recovery, particularly in the case of MIVAT, compared with the conventional transcervical approach (CTA). However, comparative evidence regarding postoperative pain outcomes remains limited. This study aims to evaluate postoperative pain outcomes among MIVAT and five remote-access approaches-breast approach (BA), bilateral axillo-breast approach (BABA), gasless transaxillary approach (GTAA), retroauricular approach (RA), and transoral approach (TOA)-in comparison with CTA. METHODS: A systematic review and network meta-analysis were conducted. PUBMED, EMBASE, and the Cochrane Library were searched through March 2025. Pain outcomes across surgical approaches were compared using a frequentist random-effects network meta-analysis. RESULTS: Sixty-one studies involving 9,780 patients were included. On postoperative day one, MIVAT was associated with the lowest pain scores, followed by the BA and TOA. At one-week and one-month follow-ups, MIVAT and TOA consistently exhibited the most favorable pain outcomes. Conversely, the RA and BABA were linked to the highest pain scores on day one and at one week. Differences in postoperative pain between robotic and endoscopic techniques within the same approach were not significant, although robotic RA and robotic TOA showed lower pain scores than those of their endoscopic counterparts. CONCLUSION: MIVAT and TOA provide superior postoperative pain outcomes than those of CTA and other remote-access approaches. Robotic techniques may offer additional benefits over endoscopic methods in selected cases. These findings may support more patient-centered surgical decision-making.
3. Ex vivo comparative study of at home bleaching products on whitening efficacy and enamel integrity.
All four at-home bleaching agents whitened enamel ex vivo, but their effects on enamel integrity varied. A 12% carbamide peroxide formulation with nano-hydroxyapatite achieved strong whitening while minimizing roughness increase and hardness loss compared with some higher-peroxide formulations.
Impact: Provides ISO-standardized, mechanistic safety-performance comparisons across widely used cosmetic dental products, directly informing product selection and patient counseling.
Clinical Implications: When enamel preservation is a priority, consider lower-peroxide formulations with remineralizing additives (e.g., nano-hydroxyapatite) and monitor acidity profiles in susceptible patients.
Key Findings
- All tested at-home bleaching agents significantly whitened enamel ex vivo.
- BlancOne (12% carbamide peroxide + nano-hydroxyapatite) outperformed Zoom and Pola in whitening and caused minimal roughness/hardness changes; Opalescence induced the most pronounced enamel alterations.
- Less acidic pH profiles (6–7) were observed for BlancOne and Opalescence versus about 5.5 for Zoom and Pola.
Methodological Strengths
- ISO 28399:2021-compliant design with standardized spectrophotometry
- Multimodal material assessment (AFM, nanoindentation, pH monitoring)
Limitations
- Ex vivo bovine enamel may not fully replicate human in vivo conditions
- Short observation window (48 h) and brand-specific findings may not generalize across all formulations
Future Directions: In vivo randomized trials assessing sensitivity, enamel microhardness, and long-term whitening durability across formulations are warranted.
To compare the efficacy and safety of at-home bleaching products on dental enamel using an ex vivo bovine enamel model. The study aimed to evaluate the whitening effectiveness and the structural impact of these treatments on enamel integrity. Four at-home bleaching agents [BlancOne Home Night + (BlancOne; 12% carbamide peroxide/4.2% hydrogen peroxide + nano-hydroxyapatite), Opalescence PF Regular (Opale; 16%/5.7% + potassium and fluoride nitrate), Zoom Nite White (Zoom; 16%/5.7% + amorphous calcium phosphate), and Pola Night (Pola; 16%/5.7% + potassium fluoride)] were tested on bovine enamel samples according to ISO 28,399:2021 standards. Whitening efficacy was measured spectrophotometrically before and 48 h after treatments. Enamel surface changes in topography and mechanical properties were analyzed using Atomic Force Microscopy (AFM) and nanoindentation. The pH values of the agents were monitored throughout the treatment to assess their acidity. All agents effectively whitened enamel, with BlancOne demonstrating greater whitening efficacy than Zoom (ΔOD: 5.7 ± 1.1 vs. 3.7 ± 0.9; p < 0.001) and Pola (ΔOD: 5.6 ± 1.7 vs. 1.8 ± 1.0; p < 0.001). No significant difference was observed between BlancOne and Opale (ΔOD: 5.1 ± 0.9 vs. 4.4 ± 1.9; p > 0.05). AFM and nanoindentation analyses revealed significant differences in the integrity of the enamel surface. BlancOne, Zoom and Pola induced only minimal increases in surface roughness and reductions in hardness, whereas Opale resulted in the most pronounced enamel alterations [Control = 4.75 (× 1000 GPa) ± 1.57; BlancOne = 3.1 ± 1.4; Opale = 0.1 ± 0.03; Zoom = 2.9 ± 1.0; Pola = 3.2 ± 0.9. Control vs BlancOne, Zoom, and Pola: p < 0.05; Control vs Opale: p < 0.001]. The pH analysis indicated that BlancOne and Opalescence had less acidic profiles (pH 6-7) than Zoom and Pola (pH ≈ 5.5). This study demonstrates that although all tested agents effectively achieve whitening, they differ in consistency and impact on enamel integrity. Among the tested agents, the formulation containing 12% carbamide peroxide (equivalent to 4.2% hydrogen peroxide) and nano-hydroxyapatite demonstrated a favorable balance between bleaching efficacy and enamel structure preservation. These findings provide valuable insights for clinicians in selecting whitening protocols that minimize enamel damage while achieving satisfactory cosmetic outcomes.